The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Model for end-stage liver disease-3.0 vs. model for end-stage liver disease-sodium: mortality prediction in Korea

  • Jeong Han Kim (Department of Internal Medicine, Konkuk University School of Medicine) ;
  • Yong Joon Cho (Department of Internal Medicine, Konkuk University School of Medicine) ;
  • Won Hyeok Choe (Department of Internal Medicine, Konkuk University School of Medicine) ;
  • So Young Kwon (Department of Internal Medicine, Konkuk University School of Medicine) ;
  • Byung-Chul Yoo (Department of Internal Medicine, Konkuk University School of Medicine)
  • Received : 2023.01.06
  • Accepted : 2023.09.01
  • Published : 2024.03.01
Download PDF
⟨ Previous Next ⟩

Abstract

Background/Aims: The model for end-stage liver disease (MELD) serves as an indicator for short-term mortality among patients diagnosed with liver cirrhosis (LC) and is used to prioritize patients for liver transplantation. In 2021, the updated version of MELD, MELD-3.0, was introduced to improve the accuracy of the mortality prediction of MELD. Therefore, this study aimed to compare the efficacy of MELD 3.0 and MELD-Na in predicting mortality among Korean patients with LC. Methods: A retrospective review was conducted using the medical records of patients diagnosed with LC who were admitted to Konkuk University Hospital From 2011 to 2021. The study calculated the predictive values of MELD-Na and MELD-3.0 for 3- and 6-months mortality using the area under the receiver operating curve (AUROC) and compared the results using the DeLong test. Results: Of the 3,034 patients enrolled in the study, 339 (11.2%) died within 3 months and 421 (14.4%) died within 6 months. The AUROCs values for predicting 3 months mortality were 0.846 for MELD-Na and 0.851 for MELD-3.0. The corresponding AUROC values for predicting 6 months mortality were 0.843 for MELD-Na and 0.848 for MELD-3.0. MELD-3.0 exhibited better discrimination ability than MELD-Na for both 3 (p = 0.03) and 6 months mortality (p = 0.01). Conclusions: Our study found a significant difference between the performance of MELD-3.0 and MELD-Na in Korean patients with LC.

Keywords

References

  1. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464-470. https://doi.org/10.1053/jhep.2001.22172
  2. Wiesner R, Edwards E, Freeman R, et al.; United Network for Organ Sharing Liver Disease Severity Score Committee. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003;124:91-96. https://doi.org/10.1053/gast.2003.50016
  3. Leise MD, Kim WR, Kremers WK, Larson JJ, Benson JT, Therneau TM. A revised model for end-stage liver disease optimizes prediction of mortality among patients awaiting liver transplantation. Gastroenterology 2011;140:1952-1960. https://doi.org/10.1053/j.gastro.2011.02.017
  4. Kim WR, Biggins SW, Kremers WK, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 2008;359:1018-1026. https://doi.org/10.1056/NEJMoa0801209
  5. Luca A, Angermayr B, Bertolini G, et al. An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis. Liver Transpl 2007;13:1174-1180. https://doi.org/10.1002/lt.21197
  6. Ruf AE, Kremers WK, Chavez LL, Descalzi VI, Podesta LG, Villamil FG. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl 2005;11:336-343. https://doi.org/10.1002/lt.20329
  7. Guy J, Somsouk M, Shiboski S, Kerlan R, Inadomi JM, Biggins SW. New model for end stage liver disease improves prognostic capability after transjugular intrahepatic portosystemic shunt. Clin Gastroenterol Hepatol 2009;7:1236-1240. https://doi.org/10.1016/j.cgh.2009.06.009
  8. Yoon JH, Jun CH, Kim JH, et al. Changing trends in liver cirrhosis etiology and severity in Korea: the increasing impact of alcohol. J Korean Med Sci 2021;36:e145.
  9. Locke JE, Shelton BA, Olthoff KM, et al. Quantifying sex-based disparities in liver allocation. JAMA Surg 2020;155:e201129.
  10. Kim WR, Mannalithara A, Heimbach JK, et al. MELD 3.0: the model for end-stage liver disease updated for the modern era. Gastroenterology 2021;161:1887-1895.e4. https://doi.org/10.1053/j.gastro.2021.08.050
  11. Asrani SK, Jennings LW, Trotter JF, et al. A model for glomerular filtration rate assessment in liver disease (GRAIL) in the presence of renal dysfunction. Hepatology 2019;69:1219-1230. https://doi.org/10.1002/hep.30321
  12. Musso G, Gambino R, Tabibian JH, et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med 2014;11:e1001680.
  13. Lai JC, Terrault NA, Vittinghoff E, Biggins SW. Height contributes to the gender difference in wait-list mortality under the MELD-based liver allocation system. Am J Transplant 2010;10:2658-2664. https://doi.org/10.1111/j.1600-6143.2010.03326.x